CHP
RARE icon

Cable Hill Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cable Hill Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-80
Closed -$4K – 1000
2017
Q3 		$4K Sell
80
-2
-2% -$119 ﹤0.01% 827
2017
Q2 		$5K Hold
82
– – ﹤0.01% 559
2017
Q1 		$6K Buy
82
+46
+128% +$3.51K ﹤0.01% 506
2016
Q4 		$3K Sell
36
-52
-59% -$3.69K ﹤0.01% 623
2016
Q3 		$6K Buy
88
+31
+54% +$1.98K ﹤0.01% 536
2016
Q2 		$3K Hold
57
– – ﹤0.01% 593
2016
Q1 		$4K Hold
57
– – ﹤0.01% 519
2015
Q4 		$7K Hold
57
– – 0.01% 421
2015
Q3 		$6K Buy
+57
New +$6.53K ﹤0.01% 467

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cable Hill Partners's RARE Position: Q4 2017 in Review

Cable Hill Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2017, closing a stake of 80 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in RARE in Q3 2015 and held it in 9 quarters. The position peaked at $7K in Q4 2015. 163 funds tracked by Wall St. Rank hold RARE as of Q4 2017.

  • Cable Hill Partners reported no remaining Ultragenyx Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • Cable Hill Partners sold 80 Ultragenyx Pharmaceutical shares in Q4 2017, an estimated $4K.
  • Cable Hill Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 9 quarters.
  • Cable Hill Partners's Ultragenyx Pharmaceutical position peaked at $7K in Q4 2015.
  • 163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2017.

Based on Cable Hill Partners's 13F filing for Q4 2017, filed 22 Feb 2018.